Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GPX4 | P36969 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | ICMT | O60725 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424475 | 1.00 | NPC1 (0.68) | NPC1RAB9APAX8JAK2TP53 | |
| SCHEMBL11344801 | 1.00 | NPC1 (0.68) | NPC1RAB9APAX8JAK2TP53 | |
| SCHEMBL7096422 | 1.00 | NPC1 (0.68) | NPC1RAB9APAX8JAK2TP53 | |
| SCHEMBL1082836 | 1.00 | NPC1 (0.68) | NPC1RAB9APAX8JAK2TP53 | |
| SCHEMBL11344796 | 1.00 | NPC1 (0.68) | NPC1RAB9APAX8JAK2TP53 | |
| SCHEMBL3055011 | 0.98 | NPC1 (0.65) | NPC1RAB9APAX8JAK2TP53 | |
| SCHEMBL1506356 | 0.93 | NPC1 (0.58) | NPC1RAB9APAX8JAK2TP53 | |
| Hydrochloric Acid SCHEMBL27532672 | 0.92 | NPC1 (0.56) | NPC1RAB9APAX8JAK2TP53 | |
| SCHEMBL10960608 | 0.86 | NPC1 (0.71) | NPC1RAB9APAX8JAK2TP53 | |
| SCHEMBL10961189 | 0.86 | NPC1 (0.71) | NPC1RAB9APAX8JAK2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-7511110-B2 | Crosslinkable polyorganosiloxane compositions | WACKER CHEMIE AG (DE) | 2009-03-31 | — | — | US | disclosed |
| CN-100404622-C | Crosslinkable polyorganosiloxane compositions | WACKER CHEMIE AG (DE) | 2008-07-23 | — | — | CN | disclosed |
| US-20060135689-A1 | Crosslinkable polyorganosiloxane compositions | WACKER CHEMIE GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
| CN-1789339-A | Crosslinkable polyorganosiloxane compositions | WACKER CHEMIE AG (DE) | 2006-06-21 | — | — | CN | disclosed |
| CN-1149869-A | Substituted sulfonamides as selective beta3 agonists for treatment of diabetes and obesity | MERCK & CO LTD (US) | 1997-05-14 | — | — | CN | disclosed |
| EP-0757674-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5561142-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-10-01 | — | — | US | disclosed |
| US-5541197-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995029159-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | disclosed |